The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
The TNF Paradox in Cancer Progression and Immunotherapy
Open accessAbstract
International audience
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357 · cited 1×
“The use of immune checkpoint inhibitors (ICI) considerably improved the prognosis for metastatic melanoma patients with an overall survival of 58% at 3 years when treated with a combination of anti-PD-1 (Nivolumab), and anti-CTLA4 (Ipilimumab) (30).”
An endotoxin-induced serum factor that causes necrosis of tumors
Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., & Williamson, B. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.9.3666 · Cited by 4,532
Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin
Pennica, D., Nedwin, G. E., Hayflick, J. S., Seeburg, P. H., Derynck, R., Palladino, M. A., Kohr, W. J., Aggarwal, B. B., & Goeddel, D. V. (1984) · Nature · doi:10.1038/312724a0 · Cited by 1,736
A novel domain within the 55 kd TNF receptor signals cell death
Tartaglia, L. A., Ayres, T. M., Wong, G. H. W., & Goeddel, D. V. (1993) · Cell · doi:10.1016/0092-8674(93)90464-2 · Cited by 1,288
Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis
Moore, R. J., Owens, D. M., Stamp, G., Arnott, C., Burke, F., East, N., Holdsworth, H., Turner, L., Rollins, B., Pasparakis, M., et al. (1999) · Nature Medicine · doi:10.1038/10552 · Cited by 839
Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation
Landsberg, J., Kohlmeyer, J., Renn, M., Bald, T., Rogava, M., Cron, M., Fatho, M., Lennerz, V., Wölfel, T., Hölzel, M., et al. (2012) · Nature · doi:10.1038/nature11538 · Cited by 632
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
Perez-Ruiz, E., Minute, L., Otano, I., Alvarez, M., Ochoa, M. C., Belsue, V., de Andrea, C., Rodriguez-Ruiz, M. E., Perez-Gracia, J. L., Marquez-Rodas, I., et al. (2019) · Nature · doi:10.1038/s41586-019-1162-y · Cited by 480
Li, C.-W., Xia, W., Huo, L., Lim, S.-O., Wu, Y., Hsu, J. L., Chao, C.-H., Yamaguchi, H., Yang, N.-K., Ding, Q., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3123 · Cited by 467
Eggermont, A. M. M., Koops, H. S., Klausner, J. M., Kroon, B. B. R., Schlag, P. M., Liénard, D., van Geel, A. N., Hoekstra, H. J., Meller, I., Nieweg, O. E., et al. (1996) · Annals of Surgery · doi:10.1097/00000658-199612000-00011 · Cited by 460
Curnis, F., Sacchi, A., Borgna, L., Magni, F., Gasparri, A., & Corti, A. (2000) · Nature Biotechnology · doi:10.1038/81183 · Cited by 419
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
Bertrand, F., Montfort, A., Marcheteau, E., Imbert, C., Gilhodes, J., Filleron, T., Rochaix, P., Andrieu-Abadie, N., Levade, T., Meyer, N., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02358-7 · Cited by 384 · cited 1×
“In an immunogenic mouse melanoma model, anti-PD-1 therapy allowed for the regression of 20% of tumors, whereas combining anti-PD-1, and anti-TNF induced the regression of 75% of them (36).”
Tumor immune evasion arises through loss of TNF sensitivity
Kearney, C. J., Vervoort, S. J., Hogg, S. J., Ramsbottom, K. M., Freeman, A. J., Lalaoui, N., Pijpers, L., Michie, J., Brown, K. K., Knight, D. A., et al. (2018) · Science Immunology · doi:10.1126/sciimmunol.aar3451 · Cited by 381
TNF signaling drives myeloid-derived suppressor cell accumulation
Zhao, X., Rong, L., Zhao, X., Li, X., Liu, X., Deng, J., Wu, H., Xu, X., Erben, U., Wu, P., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64115 · Cited by 378
Robaye, B., Mosselmans, R., Fiers, W., Dumont, J. E., & Galand, P. (1991) · PubMed Central · Cited by 349
The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans
Charles, K. A., Kulbe, H., Soper, R., Escorcio-Correia, M., Lawrence, T., Schultheis, A., Chakravarty, P., Thompson, R. G., Kollias, G., Smyth, J. F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39065 · Cited by 338
The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy
Zingg, D., Arenas-Ramirez, N., Sahin, D., Rosalia, R. A., Antunes, A. T., Haeusel, J., Sommer, L., & Boyman, O. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.007 · Cited by 330
B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis
Schioppa, T., Moore, R., Thompson, R. G., Rosser, E. C., Kulbe, H., Nedospasov, S., Mauri, C., Coussens, L. M., & Balkwill, F. R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100994108 · Cited by 328
Harrison, M. L., Obermueller, E., Maisey, N. R., Hoare, S., Edmonds, K., Li, N. F., Chao, D., Hall, K., Lee, C., Timotheadou, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.2136 · Cited by 251
Fraker, D. L., Alexander, H. R., Andrich, M., & Rosenberg, S. A. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.2.479 · Cited by 213
Expression of both TNF-α receptor subtypes is essential for optimal skin tumour development
Arnott, C. H., Scott, K. A., Moore, R. J., Robinson, S. C., Thompson, R. G., & Balkwill, F. R. (2004) · Oncogene · doi:10.1038/sj.onc.1207317 · Cited by 208
Immunotherapy Resistance by Inflammation-Induced Dedifferentiation
Mehta, A., Kim, Y. J., Robert, L., Tsoi, J., Comin-Anduix, B., Berent-Maoz, B., Cochran, A. J., Economou, J. S., Tumeh, P. C., Puig-Saus, C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1178 · Cited by 183
Torrey, H., Butterworth, J., Mera, T., Okubo, Y., Wang, L., Baum, D., Defusco, A., Plager, S., Warden, S., Huang, D., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aaf8608 · Cited by 182
Brown, E. R., Charles, K. A., Hoare, S. A., Rye, R. L., Jodrell, D. I., Aird, R. E., Vora, R., Prabhakar, U., Nakada, M., Corringham, R. E., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn054 · Cited by 181
Reinhardt, J., Landsberg, J., Schmid-Burgk, J. L., Ramis, B. B., Bald, T., Glodde, N., Lopez-Ramos, D., Young, A., Ngiow, S. F., Nettersheim, D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0395 · Cited by 169
Study of Etanercept, a Tumor Necrosis Factor-Alpha Inhibitor, in Recurrent Ovarian Cancer
Madhusudan, S., Muthuramalingam, S. R., Braybrooke, J. P., Wilner, S., Kaur, K., Han, C., Hoare, S., Balkwill, F., & Ganesan, T. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.127 · Cited by 167
Calcinotto, A., Grioni, M., Jachetti, E., Curnis, F., Mondino, A., Parmiani, G., Corti, A., & Bellone, M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101877 · Cited by 153
Donia, M., Andersen, R. S., Kjeldsen, J. W., Fagone, P., Ahmad, S. M., Nicoletti, F., Andersen, M. H., Straten, P. T., & Svane, I. M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2956 · Cited by 131
Ho, M.-Y., Tang, S., Chuang, M., Cha, T., Li, J.-Y., Sun, G.-H., & Sun, K. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0160 · Cited by 125
Li, B., Vincent, A., Cates, J., Brantley-Sieders, D. M., Polk, D. B., & Young, P. P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1565 · Cited by 115
Blocking Tumor Necrosis Factor α Enhances CD8 T-cell–Dependent Immunity in Experimental Melanoma
Bertrand, F., Rochotte, J., Colacios, C., Montfort, A., Tilkin-Mariamé, A.-F., Touriol, C., Rochaix, P., Lajoie-Mazenc, I., Andrieu-Abadie, N., Levade, T., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2524 · Cited by 113 · cited 1×
“Blocking TNF/TNFR1 signaling in vivo using targeting antibodies was able to increase the proportion of melanoma-specific CD8 T cells in the microenvironment and delayed tumor growth (18).”
Self-citationTNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade
Cervera-Carrascón, V., Siurala, M., Santos, J. M., Havunen, R., Tähtinen, S., Karell, P., Sorsa, S., Kanerva, A., & Hemminki, A. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1412902 · Cited by 112
Lesage, C., Longvert, C., Prey, S., Maanaoui, S., Dréno, B., Machet, L., Zehou, O., Kramkimel, N., Jeudy, G., Skowron, F., et al. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000268 · Cited by 79
Habtetsion, T. G., Ding, Z., Pi, W., Li, T., Lu, C., Chen, T., Xi, C., Spartz, H., Liu, K., Hao, Z., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.05.012 · Cited by 73
Elia, A. R., Grioni, M., Basso, V., Curnis, F., Freschi, M., Corti, A., Mondino, A., & Bellone, M. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2210 · Cited by 58
Draghi, A., Borch, T. H., Radic, H. D., Chamberlain, C. A., Gokuldass, A., Svane, I. M., & Donia, M. (2018) · International Journal of Cancer · doi:10.1002/ijc.32080 · Cited by 57
Liao, S., Luo, J., Li, D., Zhou, Y., Yan, B., Wei, J., Tu, J., Li, Y., Zhang, G., & Feng, Z. (2019) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-019-00508-8 · Cited by 49
Probst, P., Stringhini, M., Ritz, D., Fugmann, T., & Neri, D. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1728 · Cited by 34
Cited by
Advances in immunotherapy for hepatocellular carcinoma
Sangro, B., Sarobe, P., Hervás-Stubbs, S., & Melero, I. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00438-0 · Cited by 1,306
Strategies to improve the EPR effect: A mechanistic perspective and clinical translation
Ikeda-Imafuku, M., Wang, L. L.-W., Rodrigues, D., Shaha, S., Zhao, Z., & Mitragotri, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.043 · Cited by 330
Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy
Basu, A., Ramamoorthi, G., Albert, G., Gallen, C., Beyer, A., Snyder, C., Koski, G., Disis, M. L., Czerniecki, B. J., & Kodumudi, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669474 · Cited by 321
Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma
Chen, C., Wang, Z., Ding, Y., & Qin, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1133308 · Cited by 305
The Role of Inflammation in Cancer: Mechanisms of Tumor Initiation, Progression, and Metastasis
Nishida, A., & Andoh, A. (2025) · Cells · doi:10.3390/cells14070488 · Cited by 270
Metadata
- Authors
- Montfort, A., Colacios, C., Levade, T., Andrieu-Abadie, N., Meyer, N., & Ségui, B.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-07-31
- Volume
- 10
- Pages
- 1818-1818
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2963723040
- Cited by
- 305
- References
- 37
- FWCI
- 13.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.